Tumor associated regulatory dendritic cells

Seminars in Cancer Biology

Volumn 22, Issue 4, 2012, Pages 298-306

  Ma, Yang ^a   Shurin, Galina V ^a   Gutkin, Dmitriy W ^b   Shurin, Michael R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; Dendritic cells; Immune escape; Immune regulatory cells; Immunosuppression; Tolerance

Indexed keywords

ARGINASE; HLA G ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN E2; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

CANCER IMMUNOLOGY; CELL FUNCTION; CELL MATURATION; CELL POLARITY; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PLASMACYTOID DENDRITIC CELL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DENDRITIC CELLS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84862777888     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.02.010     Document Type: Review

References (150)

1. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-296.
2. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
3. Manicassamy S., Pulendran B. Dendritic cell control of tolerogenic responses. Immunol Rev 2011, 241:206-227.
4. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol 2002, 23:445-449.
5. Mahnke K., Schmitt E., Bonifaz L., Enk A.H., Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002, 80:477-483.
6. Reizis B., Colonna M., Trinchieri G., Barrat F., Gilliet M. Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system?. Nat Rev Immunol 2011, 11:558-565.
7. Vermi W., Soncini M., Melocchi L., Sozzani S., Facchetti F. Plasmacytoid dendritic cells and cancer. J Leukoc Biol 2011, 90:681-690.
8. Bjorck P., Leong H.X., Engleman E.G. Plasmacytoid dendritic cell dichotomy: identification of IFN-alpha producing cells as a phenotypically and functionally distinct subset. J Immunol 2011, 186:1477-1485.
9. Lin A., Schildknecht A., Nguyen L.T., Ohashi P.S. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett 2010, 127:77-84.
10. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
11. Palucka K., Ueno H., Fay J., Banchereau J. Dendritic cells and immunity against cancer. J Intern Med 2011, 269:64-73.
12. Esche C., Lokshin A., Shurin G.V., Gastman B.R., Rabinowich H., Watkins S.C., et al. Tumor's other immune targets: dendritic cells. J Leukoc Biol 1999, 66:336-344.
13. Shurin M.R. Regulation of dendropoiesis in cancer. Clin Immunol Newsletter 1999, 19:135-139.
14. Shurin M.R., Shurin G.V., Lokshin A., Yurkovetsky Z.R., Gutkin D.W., Chatta G., et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?. Cancer Metastasis Rev 2006, 25:333-356.
15. Pinzon-Charry A., Maxwell T., Lopez J.A. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005, 83:451-461.
16. Alcalay J., Kripke M.L. Antigen-presenting activity of draining lymph node cells from mice painted with a contact allergen during ultraviolet carcinogenesis. J Immunol 1991, 146:1717-1721.
17. Halliday G.M., Reeve V.E., Barnetson R.S. Langerhans cell migration into ultraviolet light-induced squamous skin tumors is unrelated to anti-tumor immunity. J Invest Dermatol 1991, 97:830-834.
18. Halliday G.M., Lucas A.D., Barnetson R.S. Control of Langerhans' cell density by a skin tumour-derived cytokine. Immunology 1992, 77:13-18.
19. Tas M.P., Simons P.J., Balm F.J., Drexhage H.A. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol Immunother 1993, 36:108-114.
20. Gabrilovich D.I., Nadaf S., Corak J., Berzofsky J.A., Carbone D.P. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996, 170:111-119.
21. Chaux P., Moutet M., Faivre J., Martin F., Martin M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 1996, 74:975-983.
22. Ninomiya T., Akbar S.M., Masumoto T., Horiike N., Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999, 31:323-331.
23. Sakakura K., Chikamatsu K., Takahashi K., Whiteside T.L., Furuya N. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2006, 55:151-159.
24. Maecker B., Mougiakakos D., Zimmermann M., Behrens M., Hollander S., Schrauder A., et al. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia 2006, 20:645-649.
25. Ormandy L.A., Farber A., Cantz T., Petrykowska S., Wedemeyer H., Horning M., et al. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 2006, 12:3275-3282.
26. Wojas K., Tabarkiewicz J., Jankiewicz M., Rolinski J. Dendritic cells in peripheral blood of patients with breast and lung cancer-a pilot study. Folia Histochem Cytobiol 2004, 42:45-48.
27. Della Bella S., Gennaro M., Vaccari M., Ferraris C., Nicola S., Riva A., et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003, 89:1463-1472.
28. Bellik L., Gerlini G., Parenti A., Ledda F., Pimpinelli N., Neri B., et al. Role of conventional treatments on circulating and monocyte-derived dendritic cells in colorectal cancer. Clin Immunol 2006, 121:74-80.
29. Kiertscher S.M., Luo J., Dubinett S.M., Roth M.D. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000, 164:1269-1276.
30. Yang T., Witham T.F., Villa L., Erff M., Attanucci J., Watkins S., et al. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res 2002, 62:2583-2591.
31. Peguet-Navarro J., Sportouch M., Popa I., Berthier O., Schmitt D., Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 2003, 170:3488-3494.
32. Katsenelson N.S., Shurin G.V., Bykovskaia S.N., Shogan J., Shurin M.R. Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function. Mod Pathol 2001, 14:40-45.
33. Onishi H., Morisaki T., Baba E., Kuga H., Kuroki H., Matsumoto K., et al. Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clin Immunol 2002, 105:286-295.
34. Pinzon-Charry A., Maxwell T., McGuckin M.A., Schmidt C., Furnival C., Lopez J.A. Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res 2006, 8:R5.
35. Aalamian M., Pirtskhalaishvili G., Nunez A., Esche C., Shurin G.V., Huland E., et al. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 2001, 46:68-75.
36. Brown R.D., Pope B., Murray A., Esdale W., Sze D.M., Gibson J., et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001, 98:2992-2998.
37. Shurin G.V., Aalamian M., Pirtskhalaishvili G., Bykovskaia S., Huland E., Huland H., et al. Human prostate cancer blocks the generation of dendritic cells from CD34+ hematopoietic progenitors. Eur Urol 2001, 39(Suppl. 4):37-40.
38. Ratta M., Fagnoni F., Curti A., Vescovini R., Sansoni P., Oliviero B., et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002, 100:230-237.
39. Satthaporn S., Robins A., Vassanasiri W., El-Sheemy M., Jibril J.A., Clark D., et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 2004, 53:510-518.
40. Kichler-Lakomy C., Budinsky A.C., Wolfram R., Hellan M., Wiltschke C., Brodowicz T., et al. Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer. Eur J Med Res 2006, 11:7-12.
41. Fricke I., Gabrilovich D.I. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 2006, 35:459-483.
42. Yang L., Carbone D.P. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 2004, 92:13-27.
43. Enk A.H., Jonuleit H., Saloga J., Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997, 73:309-316.
44. Lizee G., Radvanyi L.G., Overwijk W.W., Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006, 12:4794-4803.
45. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001, 194:769-779.
46. Kim R., Emi M., Tanabe K. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Exp Immunol 2006, 146:189-196.
47. Jonuleit H., Schmitt E., Schuler G., Knop J., Enk A.H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000, 192:1213-1222.
48. Levings M.K., Gregori S., Tresoldi E., Cazzaniga S., Bonini C., Roncarolo M.G. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005, 105:1162-1169.
49. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005, 202:919-929.
50. Akbari O., DeKruyff R.H., Umetsu D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001, 2:725-731.
51. Menges M., Rossner S., Voigtlander C., Schindler H., Kukutsch N.A., Bogdan C., et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002, 195:15-21.
52. McGuirk P., McCann C., Mills K.H., Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 2002, 195:221-231.
53. Shortman K., Heath W.R. Immunity or tolerance? That is the question for dendritic cells. Nat Immunol 2001, 2:988-989.
54. Munn D.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297:1867-1870.
55. Mellor A.L., Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4:762-774.
56. Grohmann U., Fallarino F., Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003, 24:242-248.
57. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005, 23:275-306.
58. Asselin-Paturel C., Boonstra A., Dalod M., Durand I., Yessaad N., Dezutter-Dambuyant C., et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001, 2:1144-1150.
59. Liu K., Victora G.D., Schwickert T.A., Guermonprez P., Meredith M.M., Yao K., et al. In vivo analysis of dendritic cell development and homeostasis. Science 2009, 324:392-397.
60. Naik S.H., Sathe P., Park H.Y., Metcalf D., Proietto A.I., Dakic A., et al. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat Immunol 2007, 8:1217-1226.
61. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999, 5:919-923.
62. Yoneyama H., Matsuno K., Zhang Y., Nishiwaki T., Kitabatake M., Ueha S., et al. Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol 2004, 16:915-928.
63. Matta B.M., Castellaneta A., Thomson A.W. Tolerogenic plasmacytoid DC. Eur J Immunol 2010, 40:2667-2676.
64. Decalf J., Fernandes S., Longman R., Ahloulay M., Audat F., Lefrerre F., et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med 2007, 204:2423-2437.
65. Penna G., Vulcano M., Roncari A., Facchetti F., Sozzani S., Adorini L. Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells. J Immunol 2002, 169:6673-6676.
66. Schlecht G., Garcia S., Escriou N., Freitas A.A., Leclerc C., Dadaglio G. Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. Blood 2004, 104:1808-1815.
67. Mouries J., Moron G., Schlecht G., Escriou N., Dadaglio G., Leclerc C. Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 2008, 112:3713-3722.
68. Villadangos J.A., Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008, 29:352-361.
69. Hoeffel G., Ripoche A.C., Matheoud D., Nascimbeni M., Escriou N., Lebon P., et al. Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 2007, 27:481-492.
70. Jego G., Pascual V., Palucka A.K., Banchereau J. Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun 2005, 8:124-139.
71. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848.
72. Chaperot L., Blum A., Manches O., Lui G., Angel J., Molens J.P., et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 2006, 176:248-255.
73. Zou W., Machelon V., Coulomb-L'Hermin A., Borvak J., Nome F., Isaeva T., et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001, 7:1339-1346.
74. Vermi W., Bonecchi R., Facchetti F., Bianchi D., Sozzani S., Festa S., et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003, 200:255-268.
75. Wilke C.M., Kryczek I., Zou W. Antigen-presenting cell (APC) subsets in ovarian cancer. Int Rev Immunol 2011, 30:120-126.
76. Charles J., Di Domizio J., Salameire D., Bendriss-Vermare N., Aspord C., Muhammad R., et al. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol 2010, 130:1646-1656.
77. Hartmann E., Wollenberg B., Rothenfusser S., Wagner M., Wellisch D., Mack B., et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003, 63:6478-6487.
78. Labidi-Galy S.I., Sisirak V., Meeus P., Gobert M., Treilleux I., Bajard A., et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011, 71:5423-5434.
79. Thiel A., Pries R., Jeske S., Trenkle T., Wollenberg B. Effect of head and neck cancer supernatant and CpG-oligonucleotides on migration and IFN-alpha production of plasmacytoid dendritic cells. Anticancer Res 2009, 29:3019-3025.
80. Watkins S.K., Zhu Z., Riboldi E., Shafer-Weaver K.A., Stagliano K.E., Sklavos M.M., et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011, 121:1361-1372.
81. Treilleux I., Blay J.Y., Bendriss-Vermare N., Ray-Coquard I., Bachelot T., Guastalla J.P., et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004, 10:7466-7474.
82. Cao W., Bover L. Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol Rev 2010, 234:163-176.
83. Cai D., Cao J., Li Z., Zheng X., Yao Y., Li W., et al. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer 2009, 9:102.
84. Sharma M.D., Baban B., Chandler P., Hou D.Y., Singh N., Yagita H., et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007, 117:2570-2582.
85. Ito T., Yang M., Wang Y.H., Lande R., Gregorio J., Perng O.A., et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007, 204:105-115.
86. Chen W., Liang X., Peterson A.J., Munn D.H., Blazar B.R. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008, 181:5396-5404.
87. Muller A.J., Prendergast G.C. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007, 7:31-40.
88. Norian L.A., Rodriguez P.C., O'Mara L.A., Zabaleta J., Ochoa A.C., Cella M., et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via l-arginine metabolism. Cancer Res 2009, 69:3086-3094.
89. Jahrsdorfer B., Vollmer A., Blackwell S.E., Maier J., Sontheimer K., Beyer T., et al. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 2010, 115:1156-1165.
90. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991, 174:915-924.
91. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991, 147:3815-3822.
92. Willems F., Marchant A., Delville J.P., Gerard C., Delvaux A., Velu T., et al. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994, 24:1007-1009.
93. Takayama T., Morelli A.E., Onai N., Hirao M., Matsushima K., Tahara H., et al. Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. J Immunol 2001, 166:7136-7143.
94. Steinbrink K., Wolfl M., Jonuleit H., Knop J., Enk A.H. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997, 159:4772-4780.
95. Boks M.A., Kager-Groenland J.R., Haasjes M.S., Zwaginga J.J., van Ham S.M., Ten Brinke A. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction-a comparative study of human clinical-applicable DC. Clin Immunol 2012, 142:332-342.
96. Kryczek I., Wei S., Zou L., Zhu G., Mottram P., Xu H., et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006, 177:40-44.
97. Fischer J.R., Darjes H., Lahm H., Schindel M., Drings P., Krammer P.H. Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur J Cancer 1994, 30A:2125-2129.
98. Rodeck U., Bossler A., Graeven U., Fox F.E., Nowell P.C., Knabbe C., et al. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 1994, 54:575-581.
99. Kobie J.J., Wu R.S., Kurt R.A., Lou S., Adelman M.K., Whitesell L.J., et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003, 63:1860-1864.
100. Lan Y.Y., Wang Z., Raimondi G., Wu W., Colvin B.L., de Creus A., et al. " Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol 2006, 177:5868-5877.
101. Sato K., Yamashita N., Baba M., Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003, 18:367-379.
102. Azzaoui I., Yahia S.A., Chang Y., Vorng H., Morales O., Fan Y., et al. CCL18 differentiates dendritic cells in tolerogenic cells able to prime regulatory T cells in healthy subjects. Blood 2011, 118:3549-3558.
103. Mellor A.L., Baban B., Chandler P.R., Manlapat A., Kahler D.J., Munn D.H. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2005, 175:5601-5605.
104. Rigas B., Goldman I.S., Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993, 122:518-523.
105. Benoit V., Relic B., Leval Xd.X, Chariot A., Merville M.P., Bours V. Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene 2004, 23:1631-1635.
106. Pockaj B.A., Basu G.D., Pathangey L.B., Gray R.J., Hernandez J.L., Gendler S.J., et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004, 11:328-339.
107. Chemnitz J.M., Driesen J., Classen S., Riley J.L., Debey S., Beyer M., et al. Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res 2006, 66:1114-1122.
108. Akasaki Y., Liu G., Chung N.H., Ehtesham M., Black K.L., Yu J.S. Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 2004, 173:4352-4359.
109. Baratelli F., Lin Y., Zhu L., Yang S.C., Heuze-Vourc'h N., Zeng G., et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005, 175:1483-1490.
110. Sharma S., Yang S.C., Zhu L., Reckamp K., Gardner B., Baratelli F., et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005, 65:5211-5220.
111. Kalinski P., Vieira P.L., Schuitemaker J.H., de Jong E.C., Kapsenberg M.L. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001, 97:3466-3469.
112. von Bergwelt-Baildon M.S., Popov A., Saric T., Chemnitz J., Classen S., Stoffel M.S., et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006, 108:228-237.
113. Wilczynski J.R. Cancer and pregnancy share similar mechanisms of immunological escape. Chemotherapy 2006, 52:107-110.
114. Mouillot G., Marcou C., Zidi I., Guillard C., Sangrouber D., Carosella E.D., et al. Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 2007, 68:277-285.
115. Ristich V., Liang S., Zhang W., Wu J., Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol 2005, 35:1133-1142.
116. Chang C.C., Ciubotariu R., Manavalan J.S., Yuan J., Colovai A.I., Piazza F., et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002, 3:237-243.
117. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54.
118. Park S.J., Nakagawa T., Kitamura H., Atsumi T., Kamon H., Sawa S., et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 2004, 173:3844-3854.
119. Alshamsan A. Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma. Immunopharmacol Immunotoxicol 2012, [Epub ahead of print].
120. Larmonier N., Marron M., Zeng Y., Cantrell J., Romanoski A., Sepassi M., et al. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 2007, 56:48-59.
121. Misaki K., Morinobu A., Saegusa J., Kasagi S., Fujita M., Miyamoto Y., et al. Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice. Arthritis Res Ther 2011, 13:R77.
122. Sun Y., Chin Y.E., Weisiger E., Malter C., Tawara I., Toubai T., et al. Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol 2009, 182:5899-5903.
123. Pilz A., Kratky W., Stockinger S., Simma O., Kalinke U., Lingnau K., et al. Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL. J Immunol 2009, 183:2286-2293.
124. Jackson S.H., Yu C.R., Mahdi R.M., Ebong S., Egwuagu C.E. Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J Immunol 2004, 172:2307-2315.
125. Evel-Kabler K., Song X.T., Aldrich M., Huang X.F., Chen S.Y. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 2006, 116:90-100.
126. Wang S., Yang J., Qian J., Wezeman M., Kwak L.W., Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006, 107:2432-2439.
127. Wang S., Hong S., Yang J., Qian J., Zhang X., Shpall E., et al. Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 2006, 108:4071-4077.
128. Arce F., Breckpot K., Stephenson H., Karwacz K., Ehrenstein M.R., Collins M., et al. ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. Arthritis Rheum 2011, 63:84-95.
129. Zhao F., Falk C., Osen W., Kato M., Schadendorf D., Umansky V. Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 2009, 15:4382-4390.
130. Shurin G.V., Tourkova I.L., Chatta G.S., Schmidt G., Wei S., Djeu J.Y., et al. Small rho GTPases regulate antigen presentation in dendritic cells. J Immunol 2005, 174:3394-3400.
131. Tourkova I.L., Shurin G.V., Wei S., Shurin M.R. Small rho GTPases mediate tumor-induced inhibition of endocytic activity of dendritic cells. J Immunol 2007, 178:7787-7793.
132. Shurin M.R., Naiditch H., Zhong H., Shurin G.V. Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol Ther 2011, 11:988-992.
133. Shurin G.V., Ouellette C.E., Shurin M.R. Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunol Immunother 2012, 61:223-230.
134. Liu Q., Zhang C., Sun A., Zheng Y., Wang L., Cao X. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol 2009, 182:6207-6216.
135. Munder M. Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 2009, 158:638-651.
136. Nagaraj S., Gabrilovich D.I. Myeloid-derived suppressor cells in human cancer. Cancer J 2010, 16:348-353.
137. Yoshida R., Urade Y., Tokuda M., Hayaishi O. Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. Proc Natl Acad Sci U S A 1979, 76:4084-4086.
138. Pfefferkorn E.R. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A 1984, 81:908-912.
139. Byrne G.I., Lehmann L.K., Landry G.J. Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect Immun 1986, 53:347-351.
140. Moffett J.R., Namboodiri M.A. Tryptophan and the immune response. Immunol Cell Biol 2003, 81:247-265.
141. MacKenzie C.R., Heseler K., Muller A., Daubener W. Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines. Curr Drug Metab 2007, 8:237-244.
142. Mellor A.L., Keskin D.B., Johnson T., Chandler P., Munn D.H. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 2002, 168:3771-3776.
143. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005, 11:312-319.
144. Popov A., Abdullah Z., Wickenhauser C., Saric T., Driesen J., Hanisch F.G., et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J Clin Invest 2006, 116:3160-3170.
145. Munn D.H., Sharma M.D., Hou D., Baban B., Lee J.R., Antonia S.J., et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004, 114:280-290.
146. Kwon H.K., Lee C.G., So J.S., Chae C.S., Hwang J.S., Sahoo A., et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A 2010, 107:2159-2164.
147. Ueno A., Cho S., Cheng L., Wang J., Hou S., Nakano H., et al. Transient upregulation of IDO in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes. Diabetes 2007, 56:1686-1693.
148. Curiel T.J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003, 9:562-567.
149. Krempski J., Karyampudi L., Behrens M.D., Erskine C.L., Hartmann L., Dong H., et al. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 2011, 186:6905-6913.
150. Mu C.Y., Huang J.A., Chen Y., Chen C., Zhang X.G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011, 28:682-688.